Commentary: “Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease” by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-06-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.00827/full |
| _version_ | 1819029652781400064 |
|---|---|
| author | Harma Alma Harma Alma Corina de Jong Corina de Jong Janwillem Kocks Janwillem Kocks Janwillem Kocks Thys van der Molen Thys van der Molen |
| author_facet | Harma Alma Harma Alma Corina de Jong Corina de Jong Janwillem Kocks Janwillem Kocks Janwillem Kocks Thys van der Molen Thys van der Molen |
| author_sort | Harma Alma |
| collection | DOAJ |
| first_indexed | 2024-12-21T06:17:40Z |
| format | Article |
| id | doaj.art-3fbea1edb00b40c8a9716fbb588084cd |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-21T06:17:40Z |
| publishDate | 2020-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-3fbea1edb00b40c8a9716fbb588084cd2022-12-21T19:13:20ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-06-011110.3389/fphar.2020.00827546753Commentary: “Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease” by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519Harma Alma0Harma Alma1Corina de Jong2Corina de Jong3Janwillem Kocks4Janwillem Kocks5Janwillem Kocks6Thys van der Molen7Thys van der Molen8Department of General Practice and Elderly Care Medicine, University of Groningen, University Medical Center Groningen, Groningen, NetherlandsGRIAC Research Institute, University of Groningen, University Medical Center Groningen, Groningen, NetherlandsDepartment of General Practice and Elderly Care Medicine, University of Groningen, University Medical Center Groningen, Groningen, NetherlandsGRIAC Research Institute, University of Groningen, University Medical Center Groningen, Groningen, NetherlandsGRIAC Research Institute, University of Groningen, University Medical Center Groningen, Groningen, NetherlandsGeneral Practitioners Research Institute, Groningen, NetherlandsObservational and Pragmatic Research Institute, Singapore, SingaporeDepartment of General Practice and Elderly Care Medicine, University of Groningen, University Medical Center Groningen, Groningen, NetherlandsGRIAC Research Institute, University of Groningen, University Medical Center Groningen, Groningen, Netherlandshttps://www.frontiersin.org/article/10.3389/fphar.2020.00827/fullhealth statusCOPD(MCID) minimal clinically important differenceSt. George’s Respiratory Questionnairepatient-reported outcomes |
| spellingShingle | Harma Alma Harma Alma Corina de Jong Corina de Jong Janwillem Kocks Janwillem Kocks Janwillem Kocks Thys van der Molen Thys van der Molen Commentary: “Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease” by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519 Frontiers in Pharmacology health status COPD (MCID) minimal clinically important difference St. George’s Respiratory Questionnaire patient-reported outcomes |
| title | Commentary: “Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease” by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519 |
| title_full | Commentary: “Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease” by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519 |
| title_fullStr | Commentary: “Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease” by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519 |
| title_full_unstemmed | Commentary: “Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease” by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519 |
| title_short | Commentary: “Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease” by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519 |
| title_sort | commentary healthcare professionals preferred efficacy endpoints and minimal clinically important differences in the assessment of new medicines for chronic obstructive pulmonary disease by dankers m et al in frontiers in pharmacology 2020 10 1519 |
| topic | health status COPD (MCID) minimal clinically important difference St. George’s Respiratory Questionnaire patient-reported outcomes |
| url | https://www.frontiersin.org/article/10.3389/fphar.2020.00827/full |
| work_keys_str_mv | AT harmaalma commentaryhealthcareprofessionalspreferredefficacyendpointsandminimalclinicallyimportantdifferencesintheassessmentofnewmedicinesforchronicobstructivepulmonarydiseasebydankersmetalinfrontiersinpharmacology2020101519 AT harmaalma commentaryhealthcareprofessionalspreferredefficacyendpointsandminimalclinicallyimportantdifferencesintheassessmentofnewmedicinesforchronicobstructivepulmonarydiseasebydankersmetalinfrontiersinpharmacology2020101519 AT corinadejong commentaryhealthcareprofessionalspreferredefficacyendpointsandminimalclinicallyimportantdifferencesintheassessmentofnewmedicinesforchronicobstructivepulmonarydiseasebydankersmetalinfrontiersinpharmacology2020101519 AT corinadejong commentaryhealthcareprofessionalspreferredefficacyendpointsandminimalclinicallyimportantdifferencesintheassessmentofnewmedicinesforchronicobstructivepulmonarydiseasebydankersmetalinfrontiersinpharmacology2020101519 AT janwillemkocks commentaryhealthcareprofessionalspreferredefficacyendpointsandminimalclinicallyimportantdifferencesintheassessmentofnewmedicinesforchronicobstructivepulmonarydiseasebydankersmetalinfrontiersinpharmacology2020101519 AT janwillemkocks commentaryhealthcareprofessionalspreferredefficacyendpointsandminimalclinicallyimportantdifferencesintheassessmentofnewmedicinesforchronicobstructivepulmonarydiseasebydankersmetalinfrontiersinpharmacology2020101519 AT janwillemkocks commentaryhealthcareprofessionalspreferredefficacyendpointsandminimalclinicallyimportantdifferencesintheassessmentofnewmedicinesforchronicobstructivepulmonarydiseasebydankersmetalinfrontiersinpharmacology2020101519 AT thysvandermolen commentaryhealthcareprofessionalspreferredefficacyendpointsandminimalclinicallyimportantdifferencesintheassessmentofnewmedicinesforchronicobstructivepulmonarydiseasebydankersmetalinfrontiersinpharmacology2020101519 AT thysvandermolen commentaryhealthcareprofessionalspreferredefficacyendpointsandminimalclinicallyimportantdifferencesintheassessmentofnewmedicinesforchronicobstructivepulmonarydiseasebydankersmetalinfrontiersinpharmacology2020101519 |